SCHEMBL17477113

SCHEMBL17477113

COC(=O)c1ccc(Sc2ccc(NC(C)=O)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.57
MEN1 O00255 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
ALDH1A1 P00352 3/20 0.57
LMNA P02545 2/20 0.57
MAPT P10636 4/20 0.54
RAB9A P51151 3/20 0.53
MAPK1 P28482 3/20 0.53
NPC1 O15118 2/20 0.53
KDM4E B2RXH2 2/20 0.53
HTT P42858 1/20 0.53
HDAC1 Q13547 1/20 0.52
GAA P10253 2/20 0.51
ATM Q13315 1/20 0.51
POLB P06746 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HPGD P15428 1/20 0.51
RECQL P46063 1/20 0.51
GRM8 O00222 1/20 0.51
GRM7 Q14831 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863168 0.89 MEN1 (0.69) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL6575703 0.86 CA1 (0.61) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL3959278 0.86 SMN1; SMN2 (0.64) KMT2AMEN1SMN1; SMN2ALDH1A1MAPT
SCHEMBL14563219 0.84 MEN1 (0.62) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL6323372 0.84 ALDH1A1 (0.68) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL17477114 0.83 ALDH1A1 (0.56) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL11642601 0.81 MEN1 (0.64) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL10926166 0.81 NPC1 (0.59) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL6305740 0.81 SMN1; SMN2 (0.67) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL11640630 0.80 MEN1 (0.51) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3180307-B1 PROCESS FOR THE SYNTHESIS OF DAPSONE AND ITS INTERMEDIATES SEEGPHARM SA (CH) 2019-02-13 EP disclosed
US-9845289-B2 Process for the synthesis of Dapsone and its intermediates SEEGPHARM SA (CH) 2017-12-19 US disclosed
US-20170217883-A1 PROCESS FOR THE SYNTHESIS OF DAPSONE AND ITS INTERMEDIATES SEEGPHARM SA (CH) 2017-08-03 US disclosed
EP-3180307-A1 PROCESS FOR THE SYNTHESIS OF DAPSONE AND ITS INTERMEDIATES Seegpharm SA (CH) 2017-06-21 EP disclosed
WO-2016016321-A1 PROCESS FOR THE SYNTHESIS OF DAPSONE AND ITS INTERMEDIATES SEEGPHARM SA (CH) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217883-A1 PROCESS FOR THE SYNTHESIS OF DAPSONE AND ITS INTERMEDIATES DHPS, FDPS, DAP3 KMT2A 4010/4885MEN1 3291/4885SMN1; SMN2 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.